ScholarIQanswers from OpenAlex & ORCID
Marybeth S. Hughes
ResearcherPublications, citations & collaboration network
Marybeth S. Hughes is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Marybeth S. Hughes have?
ScholarIQindexed works
Marybeth S. Hughes has 152 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Marybeth S. Hughes have?
ScholarIQcitation count
Marybeth S. Hughes has 25,657 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Marybeth S. Hughes?
ScholarIQh-index
Marybeth S. Hughes has an h-index of 41 in OpenAlex.
What is the i10-index of Marybeth S. Hughes?
ScholarIQi10-index
Marybeth S. Hughes has an i10-index of 69 in OpenAlex.
What is the OpenAlex record for Marybeth S. Hughes?
ScholarIQopenalex
The OpenAlex for Marybeth S. Hughes is on the source record.
What are the most-cited papers on Marybeth S. Hughes?
ScholarIQmost cited works
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich, Marybeth S. Hughes, James Chih‐Hsin Yang, Richard M. Sherry, Richard E. Royal, Suzanne L. Topalian, Udai S. Kammula, Nicholas P. Restifo, Zhili Zheng, Azam Nahvi, Christiaan R. de Vries, Linda Rogers-Freezer, Sharon Mavroukakis, Steven A. Rosenberg
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg, James Chih‐Hsin Yang, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Giao Q. Phan, Deborah E. Citrin, Nicholas P. Restifo, Paul F. Robbins, John R. Wunderlich, Kathleen E. Morton, Carolyn M. Laurençot, Seth M. Steinberg, Donald E. White, Mark E. Dudley
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins, Richard A. Morgan, Steven A. Feldman, James C. Yang, Richard M. Sherry, Mark E. Dudley, John R. Wunderlich, Azam Nahvi, Lee J. Helman, Crystal L. Mackall, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Catherine Lévy, Yong F. Li, Mona El‐Gamil, Susan Schwarz, Carolyn M. Laurençot, Steven A. Rosenberg
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Robert Somerville, Robert O. Carpenter, Maryalice Stetler‐Stevenson, James C. Yang, Giao Q. Phan, Marybeth S. Hughes, Richard M. Sherry, Mark Raffeld, Steven A. Feldman, Lily Lu, Yong F. Li, Lien T. Ngo, André Goy, Tatyana Feldman, David Spaner, Michael Wang, Clara C. Chen, Sarah M. Kranick, Avindra Nath, Debbie-Ann N. Nathan, Kathleen E. Morton, Mary Ann Toomey, Steven A. Rosenberg
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James Chih‐Hsin Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi‐Chia Richard Lee, Yong F. Li, Mona El‐Gamil, Steven A. Rosenberg